Shots:

• The P-III PEGASUS trial evaluates pemphigus (BTK inhibitor) vs PBO in 131 patients with newly diagnosed or relapsing mod. to sev. pemphigus in 19 countries globally
• The trial did not meet its 1EPs or 2EPs i.e.- complete remission from 29 to 37wks. with minimal doses of CS (≤10/mg day). The safety profile remained consistent with previous results & no new safety signals were observed
• Rilzabrutinib is being evaluated in the P-III trial for immune thrombocytopenia- and the P-II study for autoimmune condition IgG4-related disease. Additionally- the company plans to start P-II studies for immunological diseases in 2021

| Ref: Globe Newswire | Image: PharmaLive